(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`(19) World Intellectual Property
`Organization
`International Bureau
`
`(43) International Publication Date
`26 November 2015 (26.11.2015)
`
`P O P C T
`
`(10) International Publication Number
`WO 2015/179571 Al
`
`(51) International Patent Classification:
`A61N 1/36 (2006.01)
`
`(21) International Application Number:
`
`(22) International Filing Date:
`
`(25) Filing Language:
`
`(26) Publication Language:
`
`PCT/US20 15/03 1847
`
`20 May 20 15 (20.05.2015)
`
`English
`
`English
`
`(30) Priority Data:
`62/001,004
`14/292,491
`14/335,726
`14/335,784
`
`20 May 2014 (20.05.2014)
`30 May 2014 (30.05.2014)
`18 July 2014 (18.07.2014)
`18 July 2014 (18.07.2014)
`
`(71) Applicant: ELECTROCORE, LLC [US/US]; 150 Allen
`Road, Suite 201, Basking Ridge, New Jersey 07920 (US).
`
`(81) Designated States (unless otherwise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
`BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
`DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
`HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
`KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
`MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
`PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
`SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
`TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
`US (84) Designated States (unless otherwise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`US
`GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
`US
`TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
`US
`TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
`DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
`LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
`SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
`(72) Inventors: ERRICO, Joseph P.; 5 Tiffanys Way, Warren,
`GW, KM, ML, MR, NE, SN, TD, TG).
`New Jersey 07059 (US). MENDEZ, Steven; 10 Willow
`Drive, Chester, New Jersey 07930 (US). SIMON, Bruce Published:
`J.; 56 Pollard Road, Mountain Lakes, New Jersey 07040
`— with international search report (Art. 21(3))
`(US).
`
`(74) Agent: BOCK, Joel, N ; DENTONS US LLP, P.O. BOX
`061080 Wacker Drive Station, Willis Tower, Chicago,
`Illinois 60606 (US).
`
`(54) Title: NON-INVASIVE NERVE STIMULATION VIA MOBILE DEVICES
`
`(57) Abstract: Devices, systems, and methods
`are disclosed that allow a patient to self-treat a
`medical condition, such as a migraine head-
`ache,an epileptic seizure, a neurodegenerative
`disease, such as dementia, Alzheimer's disease,
`ischemic
`stroke, post-concussion
`syndrome,
`chronic traumatic encephalopathy or the like,
`by electrical non-invasive
`stimulation of a
`vagus nerve. The system can comprise a hand
`held stimulator which is applied to a surface of
`the patient's neck, wherein the stimulator com
`prises or is joined to a mobile device. A camera
`of the mobile device may be used to position
`and reposition the stimulator
`to a particular
`location on the patient's neck. The system may
`also comprise a base station that
`is used to
`meter the charging of a rechargeable battery
`within the stimulator. The base station and
`stimulator transmit data to one another regard
`ing the status of a stimulation session.
`
`oo
`
`LUMENIS EX1062
`Page 1
`
`

`

`TITLE OF INVENTION
`
`NON-INVASIVE NERVE STIMULATION VIA MOBILE DEVICES
`
`CROSS REFERENCE TO RELATED APPLICATIONS
`
`[0001]
`
`The present application claims the benefit of priority to U.S.
`
`Provisional Application Serial No. 62/001 ,004 filed 20 May 2014; U.S.
`
`Nonprovisional Application Serial No. 14/292,491 filed 30 May 2014; U.S.
`
`Nonprovisional Application Serial No. 14/335,726 filed 18 July 2014; and U.S.
`
`Nonprovisional Application Serial No. 14/335,784 filed 18 July 2014; each of which
`
`is incorporated herein by reference in its entirety for all purposes.
`
`BACKGROUND
`
`[0002]
`
`The field of the present disclosure relates to the delivery of energy
`
`impulses (and/or fields) to bodily tissues for therapeutic purposes. The present
`
`disclosure relates more specifically to devices and methods for treating medical
`
`conditions, such as migraine headaches, epilepsy, or others, wherein the patient
`
`uses the devices and methods as self-treatment, without the direct assistance of a
`
`healthcare professional. The energy impulses (and/or fields) that are used to treat
`
`those conditions comprise electrical and/or electromagnetic energy, delivered
`
`non-invasively to the patient, particularly to a vagus nerve of the patient.
`
`[0003]
`
`The use of electrical stimulation for treatment of medical conditions is
`
`well known. One of the most successful applications of modern understanding of
`
`the electrophysiological relationship between muscle and nerves is the cardiac
`
`pacemaker. Although origins of the cardiac pacemaker extend back into the
`
`1800's, it was not until 1950 that the first practical, albeit external and bulky,
`
`pacemaker was developed. The first truly functional, wearable pacemaker
`
`appeared in 1957, and in 1960, the first fully implantable pacemaker was
`
`developed.
`
`LUMENIS EX1062
`Page 2
`
`

`

`[0004]
`
`Around this time, it was also found that electrical
`
`leads could be
`
`connected to the heart through veins, which eliminated the need to open the chest
`
`cavity and attach the lead to the heart wall. In 1975, the introduction of the
`
`lithium-iodide battery prolonged the battery life of a pacemaker from a few months
`
`to more than a decade. The modern pacemaker can treat a variety of different
`
`signaling pathologies in the cardiac muscle, and can serve as a defibrillator as well
`
`(see U.S. Patent Number 6,738,667 to DENO, et al., the disclosure of which is fully
`
`incorporated herein by reference for all purposes). Because the leads are
`
`implanted within the patient, the pacemaker is an example of an implantable
`
`medical device.
`[0005]
`
`Another such example is electrical stimulation of the brain with
`
`implanted electrodes (deep brain stimulation), which has been approved for use in
`
`the treatment of various conditions, including pain and movement disorders such
`
`as essential tremor and Parkinson's disease [Joel S . PERLMUTTER and Jonathan
`
`W . Mink. Deep brain stimulation. Annu. Rev. Neurosci 29 (2006):229-257].
`
`[0006]
`
`Another application of electrical stimulation of nerves is the
`
`treatment of radiating pain in the lower extremities by stimulating the sacral nerve
`
`roots at the bottom of the spinal cord [Paul F. WHITE, Shitong Li and Jen W . Chiu.
`
`Electroanalgesia:
`
`Its Role in Acute and Chronic Pain Management. Anesth Analg
`
`92(2001 ):505-51 3 ; patent US6871 099, entitled Fully implantable microstimulator
`
`for spinal cord stimulation as a therapy for chronic pain, to WHITEHURST, et al].
`
`[0007]
`
`Vagus nerve stimulation (VNS, also known as vagal nerve
`
`stimulation) is a form of electrical stimulation.
`
`It was developed initially for the
`
`treatment of partial onset epilepsy and was subsequently developed for the
`
`treatment of depression and other disorders. The left vagus nerve is ordinarily
`
`stimulated at a location within the neck by first surgically implanting an electrode
`
`there and then connecting the electrode to an electrical stimulator [Patent numbers
`
`US4702254 entitled Neurocybernetic prosthesis, to ZABARA; US6341 236 entitled
`
`Vagal nerve stimulation techniques for treatment of epileptic seizures, to OSORIO
`
`LUMENIS EX1062
`Page 3
`
`

`

`et al; US5299569 entitled Treatment of neuropsychiatric disorders by nerve
`
`stimulation, to WERNICKE et al; G.C. ALBERT, CM. Cook, F.S. Prato, A.W.
`
`Thomas. Deep brain stimulation, vagal nerve stimulation and transcranial
`
`stimulation: An overview of stimulation parameters and neurotransmitter release.
`
`Neuroscience and Biobehavioral Reviews 33 (2009):1 042-1 060; GROVES DA,
`
`Brown VJ. Vagal nerve stimulation: a review of its applications and potential
`
`mechanisms that mediate its clinical effects. Neurosci Biobehav Rev
`
`29(2005):493-500; Reese TERRY, Jr. Vagus nerve stimulation: a proven therapy
`
`for treatment of epilepsy strives to improve efficacy and expand applications. Conf
`
`Proc IEEE Eng Med Biol Soc. 2009; 2009:4631 -4634; Timothy B . MAPSTONE.
`
`Vagus nerve stimulation: current concepts. Neurosurg Focus 25 (3,2008):E9, pp.
`
`1-4; ANDREWS, R.J. Neuromodulation.
`
`I . Techniques-deep brain stimulation,
`
`vagus nerve stimulation, and transcranial magnetic stimulation. Ann. N . Y . Acad.
`
`Sci. 993(2003):1-1 3 ; LABINER, D.M., Ahern, G.L. Vagus nerve stimulation
`
`therapy in depression and epilepsy: therapeutic parameter settings. Acta. Neurol.
`
`Scand. 115(2007):23-33].
`
`[0008]
`
`Chronic daily headache by definition occurs with a frequency of at
`
`least 15 headache days per month for greater than 3 months duration. Chronic
`
`migraine sufferers comprise a subset of the population of chronic headache
`
`sufferers, as do those who suffer other primary headache disorders such as
`
`chronic tension-type headache [Bert B.VARGAS, David W . Dodick. The Face of
`
`Chronic Migraine: Epidemiology, Demographics, and Treatment Strategies.
`
`Neurol Clin 27 (2009) 467-479; Peter J . GOADSBY, Richard B . Lipton, Michel D.
`
`Ferrari. Migraine - Current understanding and treatment. N Engl J Med 346
`
`(4,2002): 257- 270; Stephen D SILBERSTEIN. Migraine. LANCET 363
`
`(2004):381 -391].
`
`[0009]
`
`A migraine headache typically passes through the following stages:
`
`prodrome, aura, headache pain, and postdrome. All these phases do not
`
`necessarily occur, and there is not necessarily a distinct onset or end of each stage,
`
`LUMENIS EX1062
`Page 4
`
`

`

`with the possible exception of the aura. An interictal period follows the postdrome,
`
`unless the postrome of one migraine attack overlaps the prodrome of the next
`
`migraine attack.
`
`[0010]
`
`The prodrome stage comprises triggering events followed by
`
`premonitory symptoms. The prodrome is often characterized by fatigue,
`
`sleepiness, elation, food cravings, depression, and irritability, among other
`
`symptoms. Triggers (also called precipitating factors) such as excessive stress or
`
`sensory barrage usually precede the attack by less than 48 h . The average
`
`duration of the prodrome is 6 to 10 hours, but in half of migraine attacks, the
`
`prodrome is less than two hours (or absent), and in approximately 15% of migraine
`
`attacks, the prodrome lasts for 12 hours to 2 days.
`
`[001 1]
`
`The aura is due to cortical spreading depression within the brain.
`
`Approximately 20-30% of migraine sufferers experience an aura, ordinarily a
`
`visual aura, which is perceived as a scintillating scotoma (zig-zag line) that moves
`
`within the visual field. However, aura symptoms, regardless of their form, vary to a
`
`great extent in duration and severity from patient to patient, and also within the
`
`same individual.
`
`[0012]
`
`Although the headache phase can begin at any hour, it most
`
`commonly begins as mild pain when the patient awakens in the morning. It then
`
`gradually builds at variable rates to reach a peak at which the pain is usually
`
`described as moderate to severe. Migraine headaches often occur on both sides
`
`of the head in children, but an adult pattern of unilateral pain often emerges in
`
`adolescence. The pain is often reported as starting in the occipital/neck regions,
`
`later becoming frontotemporal.
`
`It is throbbing and aggravated by physical effort,
`
`with all stimuli tending to accentuate the headache. The pain phase lasts 4-72 h in
`
`adults and 1-72 h in children, with a mean duration generally of less than 1 day.
`
`The pain intensity usually follows a smooth curve with a crescendo with a
`
`diminuendo. After the headache has resolved, many patients are left with a
`
`LUMENIS EX1062
`Page 5
`
`

`

`postdrome that lingers for one to two days. The main complaints during the
`
`prodrome are cognitive difficulties, such as mental tiredness.
`
`[0013]
`
`For more background information on the use of noninvasive vagus
`
`nerve stimulation to treat migraine/sinus headaches, refer to co-pending,
`
`commonly assigned application number US 13/1 09,250 with publication number
`
`US201 10230701 , entitled Electrical and magnetic stimulators used to treat
`
`migraine/sinus headache and comorbid disorders to SIMON et al; and application
`
`number US 13/1 83,721 with publication number US201 102761 07, entitled
`
`Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis,
`
`sinusitis, rhinosinusitis, and comorbid disorders,
`
`to SIMON et al, which are fully
`
`incorporated by reference for all purposes.
`
`[0014]
`
`Dementia is a clinical diagnosis that is based on evidence of
`
`cognitive dysfunction in both the patient's history and in successive mental status
`
`examinations. The diagnosis is made when there is impairment
`
`in two or more of
`
`the following:
`
`learning and retaining newly acquired information (episodic
`
`declarative memory); handling complex tasks and reasoning abilities (executive
`
`cognitive functions); visuospatial ability and geographic orientation; and language
`
`functions. The diagnosis may be made after excluding potentially treatable
`
`disorders that may otherwise contribute to cognitive impairment, such as
`
`depression, vitamin deficiencies, hypothyroidism,
`
`tumor, subdural hematomas,
`
`central nervous system infection, a cognitive disorder related to human
`
`immunodeficiency virus infection, adverse effects of prescribed medications, and
`
`substance abuse [McKHANN G , Drachman D, Folstein M , Katzman R , Price D,
`
`Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the
`
`NINCDS-ADRDA Work Group under the auspices of Department of Health and
`
`Human Services Task Force on Alzheimer's Disease. Neurology
`
`34(7,1 984):939-44; David S . KNOPMAN. Alzheimer's Disease and other
`
`dementias. Chapter 409 (pp. 2274-2283)
`
`In: Goldman's Cecil Medicine, 24th Edn.
`
`(Lee Goldman and Andrew I . Schafer, Eds.). Philadelphia : Elsevier-Saunders,
`
`LUMENIS EX1062
`Page 6
`
`

`

`2012; THOMPSON S B . Alzheimers Disease: Comprehensive Review of Aetiology,
`
`Diagnosis, Assessment Recommendations and Treatment. Webmed Central
`
`AGING 201 1; 2(3): WMC001 681 , pp. 1-42].
`
`[0015]
`
`Dementia prevalence increases with age, from 5 % of those aged
`
`71-79 years to 37% of those aged 90 and older. However, despite their
`
`prevalence in old age, dementias such as Alzheimer's disease are not an integral
`
`part of the aging process [NELSON PT, Head E , Schmitt FA, Davis PR, Neltner JH,
`
`Jicha GA, Abner EL, Smith CD, Van Eldik LJ, Kryscio RJ, Scheff SW. Alzheimer's
`
`disease is not "brain aging": neuropathological, genetic, and epidemiological
`
`human studies. Acta Neuropathol 12 1(5,201 1):571 -87]. Genetics plays a role in
`
`early-onset A D (less than 1% of cases). The most powerful genetic risk factor for
`
`the more common forms of AD is the APOE e4 gene, one or more copies of which
`
`are carried by 60% of AD patients in some populations. Otherwise, the risk of A D
`
`may be increased by a low level of education, severe head injury, cerebrovascular
`
`disease, diabetes and obesity.
`
`[0016]
`
`The principal diseases that cause dementia are three
`
`neurodegenerative diseases (Alzheimer's disease, Lewy body disease, and
`
`frontotemporal
`
`lobar degeneration) and cerebrovascular disease. In the United
`
`States, Alzheimer's disease accounts for approximately 70% of cases of dementia,
`
`and vascular dementia accounts for 17% of cases. Lewy body dementia and
`
`frontotemporal
`
`lobar dementia account for the remaining 13% of cases, along with
`
`less common causes (e.g., alcoholic/toxic dementia, traumatic brain injury,
`
`normal-pressure hydrocephalus, Parkinson's dementia, Creutzfeldt-Jakob
`
`disease, and undetermined etiology). In absolute numbers, it is estimated that
`
`about 5.4 million Americans are currently living with Alzheimer's disease, and
`
`Lewy Body dementia affects about 1.3 million Americans.
`[0017]
`
`Patients with each type of dementia exhibit certain typical symptoms.
`
`In Alzheimer's disease, anterograde amnesia is a dominant symptom -- loss of the
`
`ability to create new memories of events occurring after the onset of the disease.
`
`LUMENIS EX1062
`Page 7
`
`

`

`Dementia with Lewy bodies is characterized by parkinsonism, visual hallucinations,
`
`and a rapid-eye-movement sleep disorder. Frontotemporal
`
`lobar degeneration is
`
`characterized by prominent behavioral and personality changes or by prominent
`
`language difficulties early in the course of the disease. Cerebrovascular dementia,
`
`which may be a sequela of atherosclerosis, is due to one or more cerebral
`
`infarctions (ischemic strokes) in brain locations that are responsible for the
`
`cognitive deficits. The simultaneous presence of Alzheimer's disease with
`
`vascular dementia is common, and it may be difficult to distinguish these two
`
`dementia on the basis of symptoms alone.
`
`[0018]
`
`Hour-to-hour and day-to-day changes in cognition may also be
`
`exhibited by individuals with dementia. Thus, caregivers of patients with dementia
`
`often notice that the patient may be confused and incoherent at one time, and only
`
`a few hours later, or the next day, the patient is alert and coherent. The
`
`time-course and situational antecedent of those so-called cognitive fluctuations
`
`may also be helpful in distinguishing one form of dementia from the others, using
`
`clinical scales have been developed to analyze such fluctuations (Clinician
`
`Assessment of Fluctuation, One Day Fluctuation Assessment Scale, Mayo
`
`Fluctuation Questionnaire). Dementia with Lewy bodies is associated with
`
`transient and spontaneous episodes of confusion and an inability to engage in
`
`meaningful cognitive activity, followed by reversion to a near normal level of
`
`function, often within hours. In contrast, cognitive fluctuations in Alzheimer's
`
`disease are often elicited by situations in which an underlying cognitive impairment
`
`manifests itself, typically as repetitiveness in conversation, forgetfulness in relation
`
`to a recent task or event, or other behavioral consequences of poor memory. In
`
`addition to this situational triggering aspect of a cognitive fluctuation in patients
`
`with Alzheimer's disease, the confusion is often a more enduring state shift (good
`
`days/bad days), rather than an hour-to-hour shift.
`
`[0019]
`
`The mechanism of cognitive fluctuation is unknown, either for the
`
`hour-to-hour type that is common in dementia with Lewy bodies, or the day-to-day
`
`LUMENIS EX1062
`Page 8
`
`

`

`type that is not uncommon among Alzheimer patients. However, the mechanism is
`
`clearly different than the ones involved in circadian phenomena, such as
`
`"sundowning," because the cognitive fluctuation need not occur around a
`
`particular time of day. Whatever the mechanism of cognitive fluctuations,
`
`it would
`
`be very beneficial to be able to prevent or reverse them, if only as a prophylactic or
`
`symptomatic treatment, so as to spare the patient and caregiver of the stress
`
`associated with fluctuating cognitive impairment as it relates to impairment of
`
`activities of daily living [Jorge J . PALOP, Jeannie Chin and Lennart Mucke. A
`
`network dysfunction perspective on neurodegenerative diseases. Nature
`
`443(71 3,2006):768-73; WALKER MP, Ayre GA, Cummings JL, Wesnes K ,
`
`McKeith IG, O'Brien JT, Ballard CG. The Clinician Assessment of Fluctuation and
`
`the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating
`
`confusion in dementia. Br J Psychiatry 177(2000):252-6; BRADSHAW J, Saling M ,
`
`Hopwood M , Anderson V , Brodtmann A . Fluctuating cognition in dementia with
`
`Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg
`
`Psychiatry 75(3,2004):382-7; BALLARD C, Walker M , O'Brien J, Rowan E ,
`
`McKeith I . The characterisation and impact of 'fluctuating' cognition in dementia
`
`with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry
`
`16(5,2001 ):494-8; CUMMINGS JL. Fluctuations in cognitive function in dementia
`
`with Lewy bodies. Lancet Neurol 3(5,2004):266; David R . LEE, John-Paul Taylor,
`
`Alan J . Thomas. Assessment of cognitive fluctuation in dementia: a systematic
`
`review of the literature. International Journal of Geriatric Psychiatry 27(1 0 , 201 2):
`
`989-998; BACHMAN D, Rabins P. "Sundowning" and other temporally associated
`
`agitation states in dementia patients. Annu Rev Med 57(2006):499-51 1].
`
`[0020]
`
`Early staging of the patient's disease progression makes use of
`
`biomarkers, which are cognitive, physiological, biochemical, and anatomical
`
`variables that can be measured in a patient that indicate the progression of a
`
`dementia such as AD. The most commonly measured biomarkers for A D include
`decreased Ab
`
`42 in the cerebrospinal fluid (CSF), increased CSF tau, decreased
`
`LUMENIS EX1062
`Page 9
`
`

`

`fluorodeoxyglucose uptake on PET (FDG-PET), PET amyloid imaging, and
`
`structural MRI measures of cerebral atrophy. Use of biomarkers to stage AD has
`
`developed to the point that biomarkers can be used with revised criteria for
`
`diagnosing the disease [MASDEU JC, Kreisl WC, Berman KF. The neurobiology of
`
`Alzheimer disease defined by neuroimaging. Curr Opin Neurol
`
`25(4,201 2):41 0-420; DUBOIS B, Feldman HH, Jacova C, Dekosky ST,
`
`Barberger-Gateau P, Cummings J, Delacourte A , Galasko D, Gauthier S, Jicha G ,
`
`Meguro K , O'brien J, Pasquier F, Robert P, Rossor M , Salloway S, Stern Y, Visser
`
`PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease:
`
`revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8,2007):734-46;
`
`GAUTHIER S, Dubois B, Feldman H , Scheltens P. Revised research diagnostic
`
`criteria for Alzheimer's disease. Lancet Neurol 7 (8,2008): 668-670].
`
`[0021]
`
`In the remainder of this background section, current methods of
`
`treating AD are described. As summarized here, they include methods to treat
`
`cognitive symptoms of A D patients, as well as methods that are intended to treat
`
`the underlying pathophysiological progression of AD. Because the methods
`
`described in the publications cited below have not been demonstrated to exhibit
`
`more than very modest success in treating only symptoms of AD, and no method is
`
`known to stop the progression of AD, additional methods are clearly needed. Due
`
`to the effect of vagus nerve stimulation on the patient's locus ceruleus, and the
`
`consequences of that effect, the literature below is relevant to those subjects and
`
`is emphasized in what follows.
`
`[0022]
`
`Before the currently favored amyloid cascade hypothesis of AD (and
`
`subsequent variants of that hypothesis), the focus of A D research was the search
`
`for a clearly defined neurochemical abnormality in A D patients, which would
`
`provide the basis for the development of rational therapeutic interventions that are
`
`analogous to levodopa treatment of Parkinson's disease. This led to the
`
`cholinergic hypothesis of Alzheimer's disease, which proposed that degeneration
`
`of cholinergic neurons in the basal forebrain and the associated loss of cholinergic
`
`LUMENIS EX1062
`Page 10
`
`

`

`neurotransmission in the cerebral cortex and other areas contributed significantly
`
`to the deterioration in cognitive function seen in patients with Alzheimer's disease.
`
`The symptomatic drug treatments that arose from that research are currently the
`
`mainstay of A D treatment, even though their effectiveness is very modest, and no
`
`drug delays the progression of the disease. Approved drugs for the symptomatic
`
`treatment of A D modulate neurotransmitters - either acetylcholine or glutamate:
`
`cholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and
`
`partial N -methyl-D-aspartate antagonists (memantine)
`
`[FRANCIS PT, Ramirez
`
`MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's
`
`disease. Neuropharmacology 59(4-5,201 0):221 -229; FRANCIS PT, Palmer AM,
`
`Snape M , Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a
`
`review of progress. J Neurol Neurosurg Psychiatry 66(2,1 999):1 37-47; MESULAM
`
`M.The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn
`
`Mem 11( 1 ,2004):43-49].
`
`[0023]
`
`The symptomatic treatment of A D by modulating neurotransmitters
`
`other than acetylcholine or glutamate has also been considered. One such
`
`neurotransmitter
`
`is norepinephrine (noradrenaline), which in the brain is principally
`
`synthesized in the locus ceruleus. A rationale for therapeutic modulation of
`
`norepinephrine levels has been that in AD, there is loss of noradrenergic neurons
`
`in the locus ceruleus, and the treatment would compensate for that loss
`
`[HAGLUND M , Sjobeck M , Englund E . Locus ceruleus degeneration is ubiquitous
`
`in Alzheimer's disease: possible implications for diagnosis and treatment.
`
`Neuropathology 26(6,2006):528-32; SAMUELS ER, Szabadi E . Functional
`
`neuroanatomy of the noradrenergic locus coeruleus:
`
`its roles in the regulation of
`
`arousal and autonomic function part II: physiological and pharmacological
`
`manipulations and pathological alterations of locus coeruleus activity in humans.
`
`Curr Neuropharmacol 6(3,2008):254-85; Patricia SZOT. Common factors among
`
`Alzheimer's disease, Parkinson's disease, and epilepsy: Possible role of the
`
`noradrenergic nervous system. Epilepsia 53(Suppl.
`
`,20 2):61—66].
`
`LUMENIS EX1062
`Page 11
`
`

`

`[0024]
`
`Accordingly, several
`
`investigators proposed to increase brain
`
`norepinephrine as a therapy for AD patients [EM VAZEY, VK Hinson, AC
`
`Granholm, MA Eckert, GA Jones. Norepinephrine in Neurodegeneration: A
`
`Coerulean Target. J Alzheimers Dis Parkinsonism 2(2,201 2):1 000e1 14, pp. 1-3].
`
`Administration of norepinephrine itself is not feasible as a method for increasing its
`
`levels in the central nervous system because norepinephrine, as with other
`
`catecholamines, cannot cross the blood-brain barrier. Many other drugs such as
`
`amphetamines and methylphenidate can increase norepinephrine brain levels, but
`
`they affect other neurotransmitter systems as well and have significant side effects.
`
`Consequently, less direct methods have been used or suggested as ways to
`
`increase norepinephrine levels in the central nervous system, or to activate
`
`adrenergic signaling. They include the use of special drugs that mimic
`
`norepinephrine, that serve as precursors of norepinephrine, that block the
`
`reuptake of norepinephrine, and that serve as adrenoceptor antagonists that
`
`enhances norepinephrine release [MISSONNIER P, Ragot R , Derouesne C, Guez
`
`D, Renault B . Automatic attentional shifts induced by a noradrenergic drug in
`
`Alzheimer's disease: evidence from evoked potentials. Int J Psychophysiol
`
`33(3,1 999): 243-51 ; FRIEDMAN Jl, Adler DN, Davis KL. The role of
`
`norepinephrine in the pathophysiology of cognitive disorders: potential
`
`applications to the treatment of cognitive dysfunction in schizophrenia and
`
`Alzheimer's disease. Biol Psychiatry. 46(9,1 999):1 243-52; KALININ S, Polak PE,
`
`Lin SX, Sakharkar AJ, Pandey SC, Feinstein DL. The noradrenaline precursor
`
`L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol
`
`Aging 33(8,201 2):1651 -1663; MOHS, R.C., Shiovitz, T.M., Tariot, P.N.,
`
`Porsteinsson, A .P., Baker, K.D., Feldman, P.D., 2009. Atomoxetine augmentation
`
`of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month,
`
`randomized, double-blind, placebo-controlled, parallel-trial study. Am. J . Geriatr.
`
`Psychiatry 17 , 752-759; SCULLION GA, Kendall DA, Marsden CA, Sunter D,
`
`Pardon MC. Chronic treatment with the a2-adrenoceptor antagonist fluparoxan
`
`LUMENIS EX1062
`Page 12
`
`

`

`prevents age-related deficits in spatial working memory in APP*PS1 transgenic
`mice without altering b -amyloid plaque load or astrocytosis. Neuropharmacology
`60(2-3,201 1):223-34]. Other agents that are thought to alter norepinephrine levels,
`
`via locus ceruleus activity, include chronic stress, chronic opiate treatment, and
`
`anti-depressant
`
`treatment [NESTLER EJ, Alreja M , Aghajanian GK. Molecular
`
`control of locus coeruleus neurotransmission. Biol Psychiatry
`
`46(9,1 999):1 131 - 1 139; SAMUELS, E.R., and Szabadi, E . Functional
`
`neuroanatomy of the noradrenergic locus coeruleus:
`
`its roles in the regulation of
`
`arousal and autonomic function part II: physiological and pharmacological
`
`manipulations and pathological alterations of locus coeruleus activity in humans.
`
`Curr. Neuropharmacol. 6(2008), 254-285].
`
`[0025]
`
`However, for several reasons, it is not settled that a
`
`pharmacologically-induced increase of norepinephrine, or increased signaling
`
`through the adrenergic receptors in the central nervous system, will substantially
`
`benefit A D patients. First, in patients with AD, clonidine (a centrally acting alpha2
`
`adrenergic agonist) was reported to have no effect on cognitive functions, and may
`
`even impair sustained attention and memory. Another putative
`
`alpha2-adrenoceptor agonist, guanfacine, has consistently been shown to be
`
`without effect on cognitive functions. Thus, administration of clonidine or
`
`guanfacine does not appear to provide any consistent improvement
`
`in cognitive
`
`functions, either in normal subjects or in patients with AD or other cognitive
`
`impairments. On the other hand, the alpha2-adrenoceptor antagonist, idazoxan,
`
`improved planning, sustained attention, verbal fluency, and episodic memory but
`
`impaired spatial working memory in patients with dementia of the frontal type
`
`[MARIEN MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in
`
`neurodegenerative diseases: a theory. Brain Res Brain Res Rev
`
`45(1 ,2004):38-78].
`
`[0026]
`
`Second, norepinephrine significantly worsens agitation and anxiety
`
`in A D patients, such that any potential benefits of increased norepinephrine levels
`
`LUMENIS EX1062
`Page 13
`
`

`

`may be offset by behavioral side effects, as well as cardiovascular side effects
`
`[HERRMANN N , Lanctot KL, Khan LR. The role of norepinephrine in the
`
`behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin
`
`Neurosci 16(3,2004):261 -76; PESKIND, E.R., Tsuang, D.W., Bonner, L.T.,
`
`Pascualy, M., Riekse, R.G., Snowden, M.B., Thomas, R., Raskind, M.A..
`
`Propranolol for disruptive behaviors in nursing home residents with probable or
`
`possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis. Assoc.
`
`Disord. 19(2005): 23-28].
`
`[0027]
`
`Third, loss of locus ceruleus cells in A D may lead to compensatory
`
`production of norepinephrine in other cells, such that there may actually be an
`
`increase in norepinephrine levels in some A D patients [Fitzgerald PJ. Is elevated
`
`norepinephrine an etiological factor in some cases of Alzheimer's disease? Curr
`
`Alzheimer Res 7(6,201 0):506-1 6 ; ELROD R , Peskind ER, DiGiacomo L , Brodkin
`
`Kl, Veith RC, Raskind MA. Effects of Alzheimer's disease severity on
`
`cerebrospinal
`
`fluid norepinephrine concentration. Am J Psychiatry
`
`154(1 , 1 997):25-30].
`
`[0028]
`
`Even if there is a decrease in overall brain norepinephrine levels in
`
`AD, this decrease does not necessarily occur uniformly among brain regions that
`
`are modulated by the locus ceruleus, and patterns of compensatory receptor
`
`alterations may also be complicated, with selective decreases and increases of
`
`noradrenergic receptors subtypes in different regions of the brain [HOOGENDIJK
`
`WJ, Feenstra MG, Botterblom MH, Gilhuis J, Sommer IE, Kamphorst W ,
`
`Eikelenboom P, Swaab DF. Increased activity of surviving locus ceruleus neurons
`
`in Alzheimer's disease. Ann Neurol 45(1 , 1 999):82-91 ; SZOT P, White SS,
`
`Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in
`
`the noradrenergic nervous system in the locus coeruleus and hippocampus of
`
`postmortem subjects with Alzheimer's disease and dementia with Lewy Bodies. J
`
`Neurosci 26(2006):467-478; SZOT P, White SS, Greenup JL, Leverenz JB,
`
`Peskind ER, Raskind MA. Changes in adrenoreceptors in the prefrontal cortex of
`
`LUMENIS EX1062
`Page 14
`
`

`

`subjects with dementia: evidence of compensatory changes. Neuroscience
`
`146(2007):471-480].
`
`[0029]
`
`Therefore, what is needed is not a pharmacological method that
`
`increases norepinephrine levels indiscriminately throughout
`
`the central nervous
`
`system of A D patients, but rather a method that can selectively increase (or
`
`decrease) the norepinephrine levels only where it is needed. This is true whether
`
`the increase is intended to improve cognition or whether the increase in
`
`norepinephrine levels is intended to prevent, delay or antagonize pathological
`
`biochemical changes that occur in the brains of A D patients [COUNTS SE, Mufson
`
`EJ. Noradrenaline activation of neurotrophic pathways protects against neuronal
`
`amyloid toxicity. J Neurochem 113(3,201 0):649-60; WENK GL, McGann K ,
`
`Hauss-Wegrzyniak B, Rosi S . The toxicity of tumor necrosis factor-alpha upon
`
`cholinergic neurons within the nucleus basalis and the role of norepinephrine in the
`
`regulation of inflammation:
`
`implications for Alzheimer's disease. Neuroscience
`
`12 1